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Notably, HSP27 stably overexpressed in PC-3-HSP27 cells did 
not appear as an HSP27-mediated proliferation benefit in 
the presence of AA as shown in docetaxel incubation stud-
ies.  Conclusion: In contrast to repeatedly demonstrated 
HSP27-driven chemoresistance related to chemotherapeu-
tics, our results may constitute a broader molecular mode of 
action of AA chemotherapy. AA efficacy may exert an HSP27 
suppressive role that goes beyond the primarily assumed in-
hibition of androgen biosynthesis.  © 2016 S. Karger AG, Basel 
 Introduction 
 Abiraterone acetate (AA) is a leading substance among 
the currently developed and promising antiandrogen 
drugs for the treatment of metastatic castration-resistant 
prostate cancer (mCRPC)  [1–3] . mCRPC is yet one of the 
most diagnosed malignant diseases and remains the sec-
ond-leading cause of tumour-associated deaths in male 
in the Western hemisphere  [4] . Depending on local tu-
mor progress and the presence of lymph node and bone 
metastasis, overall survival of mCRPC averaged 1.5 years 
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 Abstract 
 Introduction: Inhibition of androgen synthesis by abi-
raterone acetate (AA) entails enhanced overall survival rates 
and clinical benefit for patients with locally advanced and 
metastasized prostate cancer (PC). The expression of heat 
shock protein 27 (HSP27) is generally associated with cyto-
protection and was demonstrated to mediate chemoresis-
tance under cytostatic therapy, for instance, docetaxel treat-
ment. In this study, we investigated the impact of AA treat-
ment on HSP27 expression and PC cell growth.  Materials 
and Methods: HSP27 expression levels in docetaxel and AA-
treated PC cell lines LNCaP and PC-3 were determined by 
SDS PAGE and Western blot analysis. Proliferation assays 
were performed using a CASY Cell Counter and Analyzer 
Model TT (Roche Applied Science).  Results: Despite signifi-
cantly increased HSP27 expression in PC cells incubated with 
docetaxel, Western blot analysis implicated a significant re-
duction of the cytoprotective HSP27 in AA-treated PC cells. 
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during the last 2 decades  [5, 6] . Before 2010, docetaxel 
was the only available substance, which improved overall 
survival  [7, 8] . This implicates the necessity of targeting 
additional molecular pathways in prostate cancer (PC). 
PC progression is usually accompanied with the loss of 
physiological paracrine androgen dependence, often re-
lated with a shift to autocrine supply with androgens, and 
an increase of further factors being important for tumor 
growth and survival  [9, 10] . Moreover, mCRPC showed 
higher testosterone and dihydrotestosterone concentra-
tions as well as a significantly induced cytochrome P450 
17A1 (CYP17A1) expression within the tumour  [1, 11, 
12] . CYP17A1 is the key enzyme of gonadal and extrago-
nadal androgen synthesis by conversion of progesterone 
and pregnenolone to 17-OH progesterone and 17-OH 
pregnenolone. Recently, AA-driven inhibition of 
 CYP17A1 improved overall survival by the 4th month, 
and additionally increased the clinical outcome and 
quality of life of patients, illustrated by a fundamentally 
optimized suppression of serum androgen concentra-
tion  [1, 13] . However, currently available therapy re-
gimes, including AA, have not been fully satisfactory as 
mCRPC remains uncurable and still implies great dis-
abilities for affected men. Among the existing challenges, 
overcoming drug resistance represents one of the most 
critical factors limiting the pharmacological benefit of 
androgen depletion and other androgen receptor 
 (AR)-directed therapies. Recently discussed resistance 
mechanisms include up-regulation of CYP17A1 enzyme 
activity, AR alterations, such as mutations and AR splice 
variants, as well as arising AR-independent signalling 
pathways  [14–16] . Besides, there is growing evidence, 
that the small heat shock protein 27 (HSP27) is associ-
ated with drug resistance, AR signaling, epithelial-to-
mesenchymal transition and metastasis, with all repre-
senting pivotal anti-therapeutic mechanisms in mCRPC. 
Consequently, HSP27 itself was identified as a promising 
target in anticancer therapy  [17, 18] . Interestingly, HSP27 
has been demonstrated to considerably regulate AR ex-
pression levels, resulting in altered AR functionality  [19–
21] . It is reasonable to assume, that HSP27 could be in-
volved in – so far largely unknown – mechanisms of 
treatment resistance during AA therapy. Previously, in 
vitro experiments in PC cells showed, that (1) stable 
overexpression of HSP27 revealed significantly enhanced 
resistance to docetaxel treatment and that (2) docetaxel 
incubation was followed by a significant induction of 
HSP27 protein expression  [17] . Thus, HSP27-mediated 
cytoprotection may importantly impact therapy relapse 
and overall survival.
 In this study, we examined a possible correlation be-
tween the expression of cytoprotective HSP27 and AA 
treatment in PC cells.
 Materials and Methods 
 Cell Culture and Drug Treatment 
 Human epithelial PC cell lines LNCaP and PC-3 (Cell Lines 
Service, Eppelheim, Germany) were propagated in RPMI 1640 me-
dium with 10% foetal calf serum and 100 units/ml penicillin/strep-
tomycin (PAN Biotech) at 37   °   C and 5% CO 2 atmosphere. PC-3-
HSP27 cells stably overexpressing HSP27 were selected with 
400 μg/ml G418 (Carl Roth, Karlsruhe, Germany) as previously 
described  [17] . LNCaP cells were treated with 10 n M docetaxel 
(Sigma-Aldrich, Munich, Germany) and 10 μ M AA (Janssen-Cilag, 
Neuss, Germany). PC-3 cells were treated with 10 n M docetaxel 
and 30 μ M AA, respectively. Both cell lines were incubated with 
dimethyl sulfoxide (DMSO, Sigma-Aldrich) as appropriate vehicle 
control. Drug treatment was generally proceeded to adherent cells 
seeded 24 h prior.
 Proliferation Assay 
 Cellular proliferation was analysed in 24-well cell culture 
plates (1 ml/well) using a CASY Cell Counter and Analyzer Mod-
el TT (Roche Applied Science, Mannheim, Germany). Adherent 
cells were detached by 0.1% trypsin/0.04% ethylenediaminetet-
raacetic acid (EDTA) and resuspended in CASYton solution 
(Roche Applied Science). Measurement was performed using a 
capillary of 150 μm in diameter and cell line–specific gate settings 
to discriminate between living cells, dead cells and cellular debris. 
The number of living cells was determined in duplicates for each 
passage.
 Western Blot Analysis 
 PC cells plated onto a 6-well cell culture plate containing 3 ml 
RPMI medium were incubated with AA and docetaxel for indi-
cated time points. Adherent cells were detached by 0.1% tryp-
sin/0.04% EDTA and lysed in RIPA buffer (50 m M Tris (pH 7.5), 
150 m M NaCl, 10 m M K 2 HPO 4 , 5 m M EDTA, 10% glycerol, 1% 
Triton X-100, 0.05% sodium dodecyl sulphate, 1 m M Na 3 VO 4 , 
20 m M NaF, 0.1 m M phenylmethylsulfonyl fluoride, 20 m M 2-phos-
phoglycerate, and complete protease inhibitor cocktail from Roche 
Applied Science). Protein levels of all cell extracts were determined 
using Bradford solution (BioRad, München, Germany). Equal 
amounts of protein (10–100 μg) were separated by SDS-PAGE 
Mini-Protean system (BioRad) and transferred onto a protean ni-
trocellulose membrane (Whatman, Dassel, Germany) propagated 
with the Trans-Blot SD semi-dry transfer cell (BioRad). Mem-
branes were blocked with 1 × Roti-Block (Carl Roth). Proteins of 
interest were detected by primary antibodies directed against 
HSP27 and glyceraldehyde 3-phophate dehydrogenase (GAPDH) 
and peroxidase-coupled secondary antibodies, all obtained from 
Cell Signaling Technology (Danvers, Mass., USA). Protein signals 
were visualized with the ChemiDoc system (BioRad) using Super-
Signal West Dura Chemiluminescent Substrate (Thermo Scien-
tific, Rockford, Ill., USA) and were quantified using Image Lab 3.0 
(BioRad) software.




 Statistical analyses of at least 3 independent experiments were 
performed using the unpaired Student’s t test. Results of  *  p  ≤ 0.05, 
 * *  p  ≤ 0.01 and  * * *  p  ≤ 0.001 were considered significant. Data are 
given as mean ± SD.
 Results 
 AA Treatment Diminished HSP27 Expression in PC-3 
and LNCaP Cells 
 We have previously demonstrated that HSP27 expres-
sion in PC-3 cells significantly increased after docetaxel 
incubation  [17] . In this context, we aimed at analysing the 
effects of AA treatment on HSP27 protein expression in 
human PC cell lines LNCaP and PC-3 compared to 
docetaxel incubation. LNCaP and PC-3 cells were incu-
bated with 10 nm docetaxel or 10 μ M (LNCaP) and 30 μ M 
(PC-3) AA over a period of 120 h. HSP27 protein amounts 
were analysed by Western blot analysis and standardised 
to vehicle-treated controls. Incubation with docetaxel was 
followed by a significantly increased HSP27 protein ex-
pression in both cell lines LNCaP ( fig. 1 a; 24 h: 1; 48 h: 3.14, 
p = 0.1108; 72 h: 3.50, p = 0.0717; 96 h: 7.47, p = 0.0187; 
120 h: 16.66, p = 0.0063) and PC-3 ( fig. 1 b; 24 h: 1; 48 h: 
2.70, p = 0.0008; 72 h: 5.70, p = 0.0213; 96 h: 17.24, p = 
0.0358; 120 h: 23.54, p  = 0.0015) compared to vehicle-
treated control cells. In contrast, however, AA treatment 
was associated with a significant reduction in total HSP27 
levels in LNCaP ( fig. 1 c; 24 h: 0.91; 48 h: 0.59, p < 0.0001; 
72 h: 0.47, p = 0.0001; 96 h: 0.62, p = 0.0208; 120 h: 046, p = 
0.0063) and PC-3 cells ( fig. 1 d; 24 h: 1.01; 48 h: 1.33, p = 
0.4464; 72 h: 0.62, p = 0.0175; 96 h: 0.28, p = 0.0038; 120 h: 
0.11, p = 0.0002) compared to vehicle-treated controls.
 AA Incubation Attenuated Cellular Proliferation of 
Human PC Cell Line PC-3 Independently from HSP27 
Expression Levels 
 HSP27 was frequently characterized as a cytoprotec-
tive factor present in numerous molecular mechanisms 
causing chemoresistance. We previously demonstrated 
that overexpressed HSP27 lead to enhanced docetaxel re-
sistance in PC-3 cells, which stably express HSP27 at high 
levels (PC-3-HSP27)  [17] . To proof the impact of HSP27 
on cell growth of AA-treated PC cells, we used PC-3-









































































 Fig. 1. AA suppresses pro-oncogenic HSP27 
expression in LNCaP and PC-3 PC cells. 
Western blot analysis of HSP27 protein ex-
pression. LNCaP ( a ) and PC-3 ( b ) cells were 
incubated with 10 n M docetaxel for 120 h, 
LNCaP ( c ) and PC-3 ( d ) cells were incubat-
ed with 10 μ M (PC-3) and 30 μ M (LNCaP) 
AA for 120 h. All data were standardized to 
vehicle-treated control cells, GAPDH served 
as loading control. Docetaxel incubation in 
LNCaP and PC-3 was followed by a signifi-
cant increase of HSP27 expression. Signifi-
cantly decreased HSP27 levels were detected 
after AA incubation in both PC cell lines 
LNCaP and PC-3. Error bars indicate mean 
± SD.  *  p  ≤ 0.05,  * *  p  ≤ 0.01,  * * *  p  ≤ 0.001, 
as determined by Student’s t test. 
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line PC-3  [19] (for a representative Western blot analysis 
see insert  fig.  2 a). Cellular proliferation was measured 
over a period of 120 h. PC-3 and PC-3-HSP27 cells were 
incubated with 30 μ M AA and were compared to vehicle-
treated controls. As demonstrated in  figure 2 b, vehicle-
treated cells showed exponential cell growth, exhibiting 
no statistically significant differences between PC-3 and 
PC-3-HSP27 cells, except 120 h after the begin of vehicle 
incubation ( fig. 2 b; PC-3/vehicle:  ○ ; PC-3-HSP27/vehi-
cle;  ● ; 4 h: p = 0.9105; 24 h: p = 0.9166; 48 h: p = 0.5547; 
72 h: p = 0.1695; 96 h: p = 0.3305; 120 h: p = 0.0208). AA 
incubation was followed by obviously diminished cell 
numbers of low HSP27-level PC-3 cells and high HSP27-
level PC-3-HSP27 cells. There were no statistically sig-
nificant differences between cell numbers of both cell 
lines ( fig. 2 b; PC-3/AA:  ○ ; PC-3-HSP27/AA;  ● ; 4 h: p = 
0.9534; 24 h: p = 0.7919; 48 h: p = 0.7021; 72 h: p = 0.9511; 
96 h: p = 0.8502; 120 h: p = 0.3146).
 Discussion 
 The introduction of AA as a first-line drug was celebrat-
ed as outstanding progress for anticancer therapy of locally 
advanced PC and mCRPC, however, many questions about 
the underlying molecular mechanisms of overcoming drug 
resistance still remain unsolved. Recently, we identified AA 
as an inhibitor of proliferative and pro-oncogenic path-
ways in AR-negative and therefore androgen-insensitive 
PC cells  [22] . Thus, apart from blockade of  androgen bio-
synthesis, AA may control further AR-independent mech-
anisms involved in cytostasis and chemoresistance con-
trol. The cytoprotective factor HSP27 has repeatedly been 
proven being a substantial factor in many pro-oncogenic 
pathways in numerous tumor entities including PC. Re-
cently, its imposing cytoprotective properties were demon-
strated in a cell culture model system conceived to investi-
gate the molecular mechanisms of first-line cytostatic ther-
apy of mCRPC with docetaxel  [17] . HSP27 overexpression 
thereby was followed by a significant decrease of docetaxel-
sensitivity in PC-3 cells. Notably, accompanied with the 
increase of viability and proliferation of PC-3 cells, a 
docetaxel-dependent induction of HSP27 was detected. In 
this study, we could verify the docetaxel-dependent HSP27 
overexpression in PC-3 cells and could further demon-
strate similar results for docetaxel treated LNCaP cells 
( fig.  1 a, b). In line with this, a number of recent studies 
showed further oncogenic pathways, which are stimulated 
by AR-inhibition therapies. These oncogenic proteins are 
the most suppressed by high AR concentrations in the pre-
therapeutical setting. Thus, drug resistance is probably en-
forced by oncogenic factors, such as the enhancer of zeste 
homolog 2, signal transducer and activator of transcription 
3 and hepatocyte growth factor receptor (c-Met) pathway 
 [23–25] . From this, it is crucial to analyse a potential AA-
specific modulation of HSP27 during anticancer therapy. 
Notably, in this study a significant HSP27 suppression was 























 Fig. 2. Overexpression of HSP27 reveals no difference in cell 
growth during AA incubation.  a Representative western blot of 
basal HSP27 expression in PC-3 and PC-3-HSP27 cells. GAPDH 
served as loading control. PC-3 cells showed a low basal HSP27 
protein amount. PC-3-HSP27 cells exerted a stable HSP27 overex-
pression with high HSP27 protein levels.  b Living cell number of 
30 n M AA treated low-HSP27-level PC-3 cells (◇), PC-3-HSP27 
cells stably overexpressing HSP27 (♦), as well as vehicle-treated 
PC-3 ( ○ ) and PC-3-HSP27 cells ( ● ), respectively. Cells were ana-
lysed using a CASY Cell Counter and Analyzer Modell TT at indi-
cated time points over a period of 120 h. HSP27 overexpression 
have not resulted in any statistically significant changes of cell 
growth during AA treatment. Results are expressed as the mean ± 
SD of cell count. 
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which may explain why AA demonstrates high efficacy 
even after docetaxel therapy failure.
 Our examination contains further experimental ap-
proaches in which (1) 3 days of AA incubation were fol-
lowed by three days of docetaxel incubation, (2) 3 days of 
docetaxel incubation were followed by 3 days of AA incu-
bation, and (3) AA incubation was combined with 
docetaxel incubation (data not shown). The aim of this 
setup was to provide experimental evidence for our hy-
pothesis of AA counteracting docetaxel-mediated HSP27 
induction in an in vitro cell culture model. However, nei-
ther combination nor sequential regimen of AA and 
docetaxel has demonstrated an antithetic regulation of 
HSP27 expression. Primarily due to enhanced cytotoxic 
effects of both drugs as well as to the short-termed incu-
bation, the established in vitro model failed to appear 
suitable for this type of studies. Additionally, the signifi-
cance of sequential incubation experiments is restricted 
to intracellular drug accumulation and activity even after 
change-over of incubation conditions.
 Currently, there are no other studies reporting about a 
downregulation of striking pro-oncogenic factors like 
HSP27 in the course of AA treatment. This argues strong-
ly in favour for a so far unknown reverse interconnection 
between AA treatment and HSP27 expression. Moreover, 
we could demonstrate that HSP27 stably overexpressed 
in PC-3 cells has no significant impact on PC cell growth 
during AA incubation ( fig. 2 b). This is notable as it im-
plies that AA treatment is independent from HSP27-driv-
en cytoprotection. Moreover, HSP27 suppression by AA 
could be of great interest, as HSP27 was already shown to 
be a critical cytoprotective factor counter-acting various 
anti-proliferative cancer therapies  [26] . Consequently, a 
specific HSP27 inhibitor, Apatorsen (OGX-427, Onco-
Genex Pharmaceuticals, Bothell, Wash., USA), has been 
developed to address the problem of HSP27-driven sur-
vival mechanisms in PC therapy. This compound is cur-
rently part of phase 2 clinical trials in combination with 
prednisone (pre-chemo) and in combination with AA 
(pre- and post-chemo)  [27–29] . AA’s HSP27 inhibitory 
activity may enhance the anti-androgen activity of AA 
itself as well as the cytostatic efficacy of other anticancer 
drugs. Moreover, AA generally attenuates HSP27-driven 
cell survival, which may represent a promising approach 
for the prevention of chemoresistance and unspecific tox-
icity as well as for enhanced therapy duration and drug 
efficacy in anticancer therapy.
 Conclusion 
 This study indicated that antiandrogen therapy with 
AA is independent from HSP27-mediated cytoprotection. 
Despite HSP27 is a prevalent cell-survival factor and me-
diator of chemoresistance, HSP27 overexpression had no 
consequence for proliferation of PC cells in the presence of 
AA. This could be of great importance for future mCRPC 
treatment strategies, for example, this could be important 
in the estimation of future sequential therapy approaches 
integrating new drugs. Besides the anti-androgen efficacy 
by CYP17A1 inhibition, AA appears to exhibit a concom-
itant accessory anti-HSP27 activity, which may facilitate 
AA’s outstanding anticancer efficacy in PC therapy.
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